Circulating Tumor DNA in Multiple Myeloma: Current Insights and Future Perspectives

Area of Science:

• Hematology
• Oncology
• Molecular Diagnostics

Background:

• Circulating tumor DNA (ctDNA) is an emerging biomarker for multiple myeloma (MM).
• ctDNA analysis provides a systemic view of disease, potentially overcoming limitations of bone marrow biopsies.
• Advances in sensitive molecular techniques enhance ctDNA detection and monitoring capabilities.

Purpose of the Study:

• To explore the role of ctDNA as a minimally invasive biomarker in multiple myeloma.
• To assess the concordance of ctDNA with bone marrow genomic profiles.
• To evaluate the clinical utility of ctDNA in disease monitoring and personalized therapy.

Main Methods:

• Utilizing highly sensitive molecular techniques like digital droplet PCR and next-generation sequencing.
• Analyzing ctDNA for tumor burden, clonal evolution, and molecular heterogeneity.
• Comparing ctDNA profiles with conventional bone marrow diagnostics.

Main Results:

• Demonstrated substantial concordance between ctDNA and bone marrow genomic profiles.
• Showcased ctDNA's ability to detect resistant subclones and molecular relapse during therapy.
• Highlighted ctDNA's potential in molecular profiling, therapeutic monitoring, and minimal residual disease assessment.

Conclusions:

• ctDNA is a promising tool for dynamic disease assessment in MM, reflecting systemic and heterogeneous disease.
• ctDNA shows potential for personalized monitoring and treatment strategies, especially with novel immunotherapies.
• Challenges like low ctDNA concentration and lack of standardization need to be addressed for routine clinical implementation.